Protection from MPTP-induced neurotoxicity in differentiating mouse N2a neuroblastoma cells.
We have shown previously that subcytotoxic concentrations of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) inhibit axon outgrowth and are associated with increased neurofilament heavy chain (NF-H) phosphorylation in differentiating mouse N2a neuroblastoma cells while higher doses (> 100 microM) cause cell death. In this work we assessed the ability of potential neuroprotective agents to alleviate both MPTP-induced cell death (cytotoxicity) and MPTP-induced NF-H phosphorylation/reduction in axon outgrowth (neurotoxicity) in N2a cells induced to differentiate by dbcAMP. The neurotoxic effects of MPTP occurred in the absence of significant alterations in energy status or mitochondrial membrane potential. The hormone oestradiol (100 microM) reduced the cytotoxic effect of MPTP, but blocked di-butyryl cyclic AMP (dbcAMP)-induced differentiation, i.e. axon outgrowth. Both the cytotoxic and neurotoxic effects of MPTP were reduced by the monoamine oxidase (MAO) inhibitors deprenyl and, to a lesser extent, clorgyline. Alleviation of both neurotoxicity and cytotoxicity was also achieved by conditioned medium derived from rat C6 glioma cells. In contrast, whilst the p38 MAP kinase inhibitor, SB202190, protected cells against MPTP-induced neurotoxicity, it could not maintain cell viability at high MPTP exposures. In each case neuroprotection involved maintenance of the differentiating phenotype linked with attenuation of NF-H hyper-phosphorylation; the latter may represent a mechanism by which neuronal cells can moderate MPTP-induced neurotoxicity. The use of a simplified neuronal cell model, which expresses subtle biochemical changes following neurotoxic insult, could therefore provide a valuable tool for the identification of potential neuroprotective agents.
De Girolamo
L A
LA
Department of Life Sciences, Faculty of Science and Mathematics, Nottingham Trent University, Clifton, Nottingham, UK.
Hargreaves
A J
AJ
Billett
E E
EE
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001369:Axons / Q000187:drug effects / Q000502:physiology; D016923:Cell Death / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D017077:Culture Media, Conditioned / Q000494:pharmacology; D004594:Electrophysiology; D004958:Estradiol / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D007425:Intracellular Membranes / Q000502:physiology; D051379:Mice; D008928:Mitochondria / Q000502:physiology; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009447:Neuroblastoma / Q000473:pathology* / Q000503:physiopathology; D016900:Neurofilament Proteins / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology*; D009498:Neurotoxins / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D014407:Tumor Cells, Cultured
D017077:Culture Media, Conditioned; D007093:Imidazoles; D008996:Monoamine Oxidase Inhibitors; D016900:Neurofilament Proteins; D018696:Neuroprotective Agents; D009498:Neurotoxins; D011725:Pyridines; C051774:neurofilament protein H; D004958:Estradiol; D000255:Adenosine Triphosphate; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; C090942:4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole